Why invest

Our successful business model provides a solid platform for growth. We combine a diverse portfolio with excellent financial discipline to deliver outstanding value for shareholders.

A firm foundation for future growth

  • Leading supplier of both generic injectable and non-injectable products in the US
  • Leading market position in MENA (second largest pharmaceutical company by sales) and a growing presence in Europe
  • Trusted partner known for our commitment to quality and reliability of supply
  • Broad portfolio of high-quality products¬†
  • Agile supply chain, flexible manufacturing and leading technical capabilities
$ 2,875 m Group core revenue
$ 707 m Group core operating profit
18 % Return on capital invested

An increasingly diverse portfolio and pipeline

  • Growing presence in specialty and complex products, which offer less competition and more potential for future margin growth
  • Focus on higher-value therapeutic areas such as cardiovascular, central nervous system (CNS) and oncology
  • Annual investment in R&D to ensure we are consistently
    launching new products across our markets
  • Strong track record of value-creating partnerships, strategic
    acquisitions and geographic expansion, to enhance pipeline
    and access to new markets
5 % R&D spend as % of revenue
157 launches in 2023 across our markets
250 + projects in pipeline

A strong balance sheet and robust cash generation

  • Good cash flow generation, with $608 million operating cash flow in 2023
  • Highly disciplined approach to cash management and acquisitions
  • Strong balance sheet that provides financial flexibility to
    support future growth, and low leverage of 1.2x net debt/
    core EBITDA
1.2 x net debt/core EBITDA
$ 608 m operating cash flow
21 % operating cash flow/revenue

A proven track record of delivery for shareholders

  • A clear vision for growth
  • Group revenue compound annual growth rate (CAGR) of 7% and core EBITDA CAGR of 8% since 2018
  • Total shareholder return of 76% over the last ten years
  • Progressively increasing dividend
17.7 % return on invested capital
5 % group revenue growth at five-year CAGR
76 % TSR over last ten years

All figures for year ending 31 December 2023. 

Notice of results

Press Release, Corporate 15 July 2024

Hikma launches Sodium Acetate Injection, USP, in the US

Press Release, Product 11 July 2024

Hikma – A legacy of quality for a better future

Insight, Corporate 24 June 2024

Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D

Press Release, Corporate 17 June 2024

Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House mee...

Press Release, Corporate 06 June 2024

Hikma opens new UK office to support NHS supply, strengthening European presence

Press Release, Corporate 03 June 2024

Hikma enters the Spanish generic injectables market, strengthening its European presence

Press Release, Corporate 20 May 2024

Hikma launches Midazolam Injection, USP, in a prefilled syringe in the US

Press Release, Corporate 08 May 2024

Bringing Better Health Within Reach: Hikma’s journey to become the Partner of choice in MENA

Insight, Corporate 29 April 2024

Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated

Press Release, Financial Results 25 April 2024
Related content

Recent results